Tekla Capital Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Tekla Capital Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,772	Closed	-$422K	–	207
2018 Q4	$422K	Sell	10,772 -11,274	-51%	-$489K	0.02%	191
2018 Q3	$1.2M	Hold	22,046	–	–	0.04%	177
2018 Q2	$1.82M	Hold	22,046	–	–	0.07%	138
2018 Q1	$1.47M	Sell	22,046 -16,660	-43%	-$962K	0.06%	149
2017 Q4	$1.99M	Buy	38,706 +14,406	+59%	+$1.03M	0.08%	127
2017 Q3	$2.17M	Hold	24,300	–	–	0.08%	118
2017 Q2	$1.45M	Hold	24,300	–	–	0.05%	124
2017 Q1	$1.3M	Hold	24,300	–	–	0.05%	123
2016 Q4	$1.21M	Buy	+24,300	New	+$1.3M	0.05%	124

Other funds holding ONCE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Tekla Capital Management's ONCE Position: Q1 2019 in Review

Tekla Capital Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 10,772 shares — an estimated $422K sold.

Tekla Capital Management first reported a position in ONCE in Q4 2016 and held it in 9 quarters. The position peaked at $2.17M in Q3 2017. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

Tekla Capital Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Tekla Capital Management sold 10,772 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $422K.
Tekla Capital Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2016 and held it in 9 quarters.
Tekla Capital Management's Spark Therapeutics, Inc. Common Stock position peaked at $2.17M in Q3 2017.
199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.